To include your compound in the COVID-19 Resource Center, submit it here.

Bavarian Nordic reports Phase II data for MVA-BN RSV for respiratory syncytial virus

In September, Bavarian Nordic A/S (CSE:BAVA) reported data from a Phase II trial in 421 healthy

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE